Integral Diagnostics Stock Current Valuation
| IDX Stock | 2.91 0.01 0.34% |
Valuation analysis of Integral Diagnostics helps investors to measure Integral Diagnostics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Integral Diagnostics' Change In Cash is comparatively stable compared to the past year. Free Cash Flow is likely to gain to about 44.4 M in 2024, whereas Total Cash From Operating Activities is likely to drop slightly above 36.6 M in 2024. Fundamental drivers impacting Integral Diagnostics' valuation include:
Price Book 2.2643 | Enterprise Value 998.5 M | Enterprise Value Ebitda 148.3036 | Price Sales 1.4545 | Forward PE 22.4719 |
Fairly Valued
Today
Please note that Integral Diagnostics' price fluctuation is slightly risky at this time. Calculation of the real value of Integral Diagnostics is based on 3 months time horizon. Increasing Integral Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Integral Diagnostics' intrinsic value may or may not be the same as its current market price of 2.91, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.91 | Real 2.88 | Hype 2.9 | Naive 2.81 |
The intrinsic value of Integral Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Integral Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Integral Diagnostics helps investors to forecast how Integral stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Integral Diagnostics more accurately as focusing exclusively on Integral Diagnostics' fundamentals will not take into account other important factors: Integral Diagnostics Company Current Valuation Analysis
Integral Diagnostics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Integral Diagnostics Current Valuation | 998.53 M |
Most of Integral Diagnostics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integral Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Integral Diagnostics has a Current Valuation of 998.53 M. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The current valuation for all Australia stocks is notably lower than that of the firm.
Integral Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integral Diagnostics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integral Diagnostics could also be used in its relative valuation, which is a method of valuing Integral Diagnostics by comparing valuation metrics of similar companies.Integral Diagnostics is currently under evaluation in current valuation category among its peers.
Integral Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | 0.0336 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 998.53 M | ||||
| Shares Outstanding | 233.96 M | ||||
| Shares Owned By Insiders | 13.46 % | ||||
| Shares Owned By Institutions | 27.36 % | ||||
| Price To Book | 2.26 X | ||||
| Price To Sales | 1.45 X | ||||
| Revenue | 469.7 M | ||||
| Gross Profit | 143.76 M | ||||
| EBITDA | 12.33 M | ||||
| Net Income | (60.7 M) | ||||
| Total Debt | 357.8 M | ||||
| Book Value Per Share | 1.29 X | ||||
| Cash Flow From Operations | 66.16 M | ||||
| Earnings Per Share | (0.26) X | ||||
| Target Price | 3.16 | ||||
| Number Of Employees | 1.98 K | ||||
| Beta | 0.68 | ||||
| Market Capitalization | 683.17 M | ||||
| Total Asset | 744.28 M | ||||
| Retained Earnings | (24.96 M) | ||||
| Working Capital | (10.86 M) | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 744.28 M | ||||
| Last Dividend Paid | 0.058 |
About Integral Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integral Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integral Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integral Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integral Stock Analysis
When running Integral Diagnostics' price analysis, check to measure Integral Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integral Diagnostics is operating at the current time. Most of Integral Diagnostics' value examination focuses on studying past and present price action to predict the probability of Integral Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integral Diagnostics' price. Additionally, you may evaluate how the addition of Integral Diagnostics to your portfolios can decrease your overall portfolio volatility.